Direct answer. Viral hepatitis is liver inflammation caused by a hepatitis virus. A, B, C, D and E differ in how they spread, whether infection can persist and how prevention or treatment works. Symptoms overlap and may be absent, so an appropriate blood-test pathway is needed to identify the infection. A generic liver test or a supplement claim cannot determine which virus is present. CDC August2025 clinical overview.
- Hepatitis A does not become chronic; B and C can persist, while D requires hepatitis B.
- Hepatitis E is usually acute, but chronic infection can occur in people with weakened immunity.
- Vaccination, post-exposure prevention and antiviral treatment are different tasks.
- A reactive hepatitis C antibody result needs RNA testing to establish current infection.
- New jaundice needs urgent medical assessment; bleeding or severe deterioration can be an emergency.
Table of contents
- Evidence summary
- What viral hepatitis means, and other causes of liver inflammation
- A, B, C, D and E: transmission and persistence
- Supportive care, antiviral treatment and specialist monitoring
- Food, alcohol and the limits of liver supplements
- Blood tests, antibody results and prevention decisions
- Jaundice, bleeding and severe-illness warning signs
- Medicines, immunosuppression and hepatitis B reactivation
- Pregnancy, children, transplant recipients and recent exposure
- Results, contact precautions and the follow-up plan
- Why laboratory antiviral findings do not establish a cure
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Question | Evidence role | Interpretation / confidence |
|---|---|---|
| Can symptoms identify the virus? | Clinical and testing education | No. Similar symptoms or no symptoms make appropriate testing important. |
| Does every virus become chronic? | Virus-specific definitions | No. A is acute; B/C can persist; D requires B; E can persist with weakened immunity. |
| Is vaccination the same as treatment? | Prevention and care roles | No. An exposure, existing infection and long-term damage need different decisions. |
| Does a positive HCV antibody prove active infection? | Original testing algorithm | No. RNA testing clarifies current infection, with recent-exposure and specimen exceptions. |
| Does public source funding clear drug trials? | Source audit | No. Original authors, sponsors and supplied products require their own checks. |
Confidence is good in the virus distinctions, testing roles and urgency of the precautions described. Treatment statements explain attributed clinical care; they are not a newly conducted systematic review or financially cleared numerical efficacy ranking. An independently verified supplement replacement was not established. Public funding does not make every underlying drug or vaccine trial independent.
What viral hepatitis means, and other causes of liver inflammation
Hepatitis describes inflammation of the liver, rather than one specific infection. The liver helps process nutrients and medicines and performs other essential functions. A viral diagnosis names a cause of inflammation; it does not, by itself, describe the amount of liver damage or explain every symptom. Current national explanation.
Other causes include alcohol-associated injury, autoimmune disease and selected medicine or toxin effects. These are not caught in the same way as a hepatitis virus. A person may also have more than one liver condition, so the assessment should not end with a remembered label. Viral and non-viral distinctions.
Acute means a short-term infection; chronic means infection persists. Chronic does not mean symptoms must be constant. Someone can feel well while needing assessment or monitoring. Ask which virus has actually been demonstrated and whether the clinician is discussing infection, inflammation, fibrosis or established cirrhosis. Clinical overview.
A, B, C, D and E: transmission and persistence
| Virus | Main route to discuss | Persistence distinction |
|---|---|---|
| A | Ingestion of virus from contaminated food/water or close contact | Acute; does not become chronic. |
| B | Infected blood or relevant body fluids; birth exposure can matter | Acute or chronic. |
| C | Predominantly exposure to infected blood | Can become chronic. |
| D | Relevant blood/body-fluid exposure in someone with hepatitis B | Requires HBV; coinfection and later superinfection are different. |
| E | Contaminated water or selected undercooked animal foods | Usually acute; chronic infection is possible with weakened immunity. |
These summaries come from the CDC A/B/C overview and NIDDK D/E originals. Exposure routes overlap without making the viruses interchangeable. Having one does not prove another has been excluded.
Hepatitis E deserves a distinct food and water history. Relevant exposure may occur locally as well as during travel. The dated NIDDK page’s absolute developed-country wording and older prevalence estimates are not adopted. Ask about the actual exposure and immune state rather than using nationality or travel history as a rule-out test. Current HEV context.
Supportive care, antiviral treatment and specialist monitoring
Treatment begins with identifying the virus and assessing illness severity. Hepatitis A generally receives supportive care, while severe presentations may need hospital care. Supportive care means addressing symptoms, intake and complications; it is not a statement that every symptomatic person can manage safely at home. Acute A care context.
For hepatitis B, management may involve monitoring and antiviral treatment according to the clinical assessment. A chronic-infection diagnosis does not select a drug or starting date on its own. Ask what the current plan aims to control and which tests will show whether the plan needs changing. Attributed treatment categories.
Hepatitis C can be treated with antiviral medicines intended to clear infection. CDC advises timely treatment for confirmed infection rather than a waiting period to see whether acute infection becomes chronic. This is clinical guidance, not an independently reproduced cure percentage or a brand ranking. Current treatment role.
Hepatitis D and persistent hepatitis E require their own specialist assessment. A medicine used for another hepatitis virus cannot be assumed to control these infections. Pregnancy, weakened immunity and advanced liver injury change suitability and follow-up. This overview supplies no jurisdiction-specific drug approval claim or personal regimen. D context; E context.
Food, alcohol and the limits of liver supplements
Food and fluids support recovery and nutrition; they do not identify or eradicate a virus. Discuss ongoing nausea, vomiting or difficulty maintaining intake. A person with kidney, heart or advanced liver problems may need an individual fluid plan, rather than interpreting general hydration advice as an unlimited target. Supportive-care advice; Current poor-intake warnings.
Avoid alcohol during an acute liver infection and ask the treating team about continuing liver-health care. Tell the team about all herbal remedies, vitamins and products marketed for detoxification or liver repair. Some products or medicines can worsen liver injury. Ingredient-review precautions.
No independently verified supplement replacement for hepatitis vaccination, post-exposure prevention or antiviral treatment was established in this review. A change in an enzyme measurement does not alone prove viral clearance. Nutritional replacement for a documented deficiency is a different goal from treating infection.
Blood tests, antibody results and prevention decisions
Blood testing must match the question. Liver enzymes can indicate injury but do not name the virus. Infection testing, a measure of liver function and an assessment of scarring answer different questions. Ask what each requested result will establish and which results remain pending. Virus-specific testing framework.
For hepatitis C, a reactive antibody result can reflect current infection, resolved past infection or a false-positive result. Detection of HCV RNA establishes current infection in the diagnostic pathway. Recent exposure and immune problems can also change interpretation of an initially negative antibody result. Actual CDC testing algorithm.
Hepatitis A and B vaccination can prevent their corresponding infections; there is no hepatitis C vaccine in the current CDC source. Protection against B can also prevent D infection in someone not already infected with B. These are distinct from treating established infection. Local vaccine policies differ. A/B/C prevention; D dependence and prevention.
After a possible hepatitis A exposure, seek clinical advice promptly rather than waiting for symptoms. US CDC guidance gives a two-week post-exposure prevention window, with the actual vaccine or immune-globulin decision dependent on circumstances. That timing is a reason for prompt assessment, not permission to wait until the deadline. Original US prevention framework.
Jaundice, bleeding and severe-illness warning signs
New yellow skin or whites of the eyes requires urgent medical assessment. Jaundice has several possible causes and cannot be diagnosed as a particular hepatitis virus from appearance. It may be less noticeable on darker skin. Current urgent-contact advice.
Vomiting blood always needs medical help. Blood with faintness, confusion, black stools, rapid breathing or feeling unwell needs emergency assessment. Use the local emergency service and do not drive yourself. A familiar liver diagnosis does not make a new bleeding episode safe to observe. Bleeding urgency.
Persistent poor intake, reduced urination or dizziness needs prompt advice. Severe breathing difficulty, confusion or difficulty waking can be emergency signs. These warnings do not identify the virus; they identify a person who needs timely care. Serious dehydration and shock signs.
Chronic B or C infection can lead to cirrhosis, liver failure or cancer. Not every infected person develops the same complication, and an average outcome figure cannot predict an individual. Ask which complication the monitoring plan addresses. Long-term complication context.
Medicines, immunosuppression and hepatitis B reactivation
Give the clinical team a complete list of prescriptions, nonprescription medicines and supplements. Liver injury, kidney function and other infections can affect a medicine decision. Do not add a liver product or change a prescribed antiviral based on a general online guide. Medicine and supplement review.
Hepatitis B can reactivate in selected circumstances, including immune-suppressing treatment and treatment for hepatitis C. Tell oncology, transplant and other treating teams about past as well as current HBV results before treatment planning. The relevant tests and prevention decisions require the actual medicine and history. Reactivation context.
A past infection result is therefore not always irrelevant once symptoms settle. Keep the original results and share them when care changes. This is a coordination precaution, not a universal instruction to start another medicine or interrupt necessary immune treatment.
Pregnancy, children, transplant recipients and recent exposure
Pregnancy, a weakened immune system or another liver condition changes assessment. Hepatitis E can be particularly serious in pregnancy; chronic HEV is also relevant in some immunocompromised people. Do not dismiss jaundice or deterioration as ordinary pregnancy symptoms. Current high-risk context; Selected chronic-infection context.
Children need an age-appropriate testing and prevention pathway. Adult screening, medicine and vaccine instructions cannot be copied into infant care. Possible birth exposure should be discussed with the maternity and paediatric teams. Birth exposure context.
A recent blood or needlestick exposure needs prompt assessment even without symptoms. Bring the date, event and available vaccine/test history; do not delay while trying to judge risk from the source person’s appearance. Exposure, testing and prevention roles.
Results, contact precautions and the follow-up plan
Ask for the virus name, interpretation of the tests, assessment of liver damage and next action in writing. Clarify who will discuss outstanding results and whether a second specimen or additional test is needed. A result labelled positive is not a complete care plan.
Discuss how to reduce transmission in the actual diagnosis, whether close contacts need advice and which local work, school, food-handling or donation rules apply. Hand hygiene and blood-exposure precautions address different pathways; do not apply one virus’s exclusion period to all five. Transmission distinctions.
Agree on the purpose of follow-up, including symptoms, laboratory results and any liver assessment. Ask how care continues if medicines change, a pregnancy begins or another specialist becomes involved. This guide provides no personal dose, medicine-withdrawal schedule or guaranteed recovery date.
Why laboratory antiviral findings do not establish a cure
Cell and animal studies can investigate viral entry, immune responses or a proposed ingredient’s activity. They cannot establish safe human treatment, viral clearance or prevention of liver failure. Relevant human studies must specify the virus, clinical population, comparator, important outcomes, follow-up and financial chain. A biomarker change is not automatically a meaningful cure. Manufacturer-funded or supplied-product evidence is excluded from the independent efficacy verdict.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 19 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The illness has no corporate owner or manufacturing country. Pharmaceutical and vaccine manufacturers, diagnostic suppliers, care providers and supplement sellers can earn income around prevention, diagnosis and treatment. The source audit below separates institutional income, permitted gift routes, outside-reviewer interests and original treatment evidence. Unknown allocation remains unknown; an interest is not an allegation of improper conduct.
A funding tier measures proximity to the subject; a credibility grade reflects transparency and accuracy incentives. Tier4 producer or commercially supported efficacy is excluded from an independent benefit verdict even when a source is free. Separate2025–2026 disclosures do not establish payments for a December2024 NIDDK page. The infographic summarises these disclosed relationships; it does not invent proportions of a page budget.
| Source | Funding / backers | Country / jurisdiction | Independence / credibility / gaps | Role in this article |
|---|---|---|---|---|
| NIDDK viral-hepatitis series, December2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. Credited outside reviewer: The series credits Paul Martin, Anna Lok, Jordan Feld and Kenneth Sherman. Separate Martin, Lok/Feld and Sherman originals disclose drug-company relationships. These separate declarations do not prove a company funded the December2024 NIDDK page; contemporaneous page compensation and original trial funds are unclosed. | United States federal education, Bethesda; credited reviewer location: Miami/Ann Arbor/Cincinnati, United States, and Toronto, Canada; distinct series reviewers. Local clinical and vaccine policies differ. | Tier 3 for relevant commercially connected outside reviewers; public institution separately identified. C provisional — actual December2024 patient original checked for selected definitions, testing or care roles. Public educational accountability supports accuracy; simplification, credited reviewer interests and unclosed contemporaneous/trial finance limit independent efficacy use. No numerical treatment ranking or obsolete approval claim adopted. | Virus-family distinctions and credited outside reviewers |
| NIDDK hepatitis A, December2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. Credited outside reviewer: Paul Martin (University of Miami): own society profile declares past consultancy for AbbVie, Gilead, Merck and Mallinckrodt; disclosure period unclosed. These separate declarations do not prove a company funded the December2024 NIDDK page; contemporaneous page compensation and original trial funds are unclosed. | United States federal education, Bethesda; credited reviewer location: Miami, Florida, United States; University of Miami. Local clinical and vaccine policies differ. | Tier 3 for relevant commercially connected outside reviewers; public institution separately identified. C provisional — actual December2024 patient original checked for selected definitions, testing or care roles. Public educational accountability supports accuracy; simplification, credited reviewer interests and unclosed contemporaneous/trial finance limit independent efficacy use. No numerical treatment ranking or obsolete approval claim adopted. | Acute infection and selected supportive-care precautions |
| NIDDK hepatitis B, December2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. Credited outside reviewer: Anna Lok (University of Michigan): 2025 original guideline declarations lists Novo Nordisk monitoring-board and multiple drug-company consultancy roles. These separate declarations do not prove a company funded the December2024 NIDDK page; contemporaneous page compensation and original trial funds are unclosed. | United States federal education, Bethesda; credited reviewer location: Ann Arbor, Michigan, United States; University of Michigan. Local clinical and vaccine policies differ. | Tier 3 for relevant commercially connected outside reviewers; public institution separately identified. C provisional — actual December2024 patient original checked for selected definitions, testing or care roles. Public educational accountability supports accuracy; simplification, credited reviewer interests and unclosed contemporaneous/trial finance limit independent efficacy use. No numerical treatment ranking or obsolete approval claim adopted. | Persistence, complications and reactivation context |
| NIDDK hepatitis D, December2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. Credited outside reviewer: Anna Lok (University of Michigan): 2025 original guideline declarations lists Novo Nordisk monitoring-board and multiple drug-company consultancy roles. These separate declarations do not prove a company funded the December2024 NIDDK page; contemporaneous page compensation and original trial funds are unclosed. | United States federal education, Bethesda; credited reviewer location: Ann Arbor, Michigan, United States; University of Michigan. Local clinical and vaccine policies differ. | Tier 3 for relevant commercially connected outside reviewers; public institution separately identified. C provisional — actual December2024 patient original checked for selected definitions, testing or care roles. Public educational accountability supports accuracy; simplification, credited reviewer interests and unclosed contemporaneous/trial finance limit independent efficacy use. No numerical treatment ranking or obsolete approval claim adopted. | Dependence on HBV and coinfection/superinfection distinction |
| NIDDK hepatitis E, December2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. Credited outside reviewer: Kenneth Sherman (then credited University of Cincinnati): July2026 original educational disclosure lists GSK consultancy and Atea research support; the separate course is Gilead-supported. These separate declarations do not prove a company funded the December2024 NIDDK page; contemporaneous page compensation and original trial funds are unclosed. | United States federal education, Bethesda; credited reviewer location: Cincinnati, Ohio, United States; University of Cincinnati at page credit. Local clinical and vaccine policies differ. | Tier 3 for relevant commercially connected outside reviewers; public institution separately identified. C provisional — actual December2024 patient original checked for selected definitions, testing or care roles. Public educational accountability supports accuracy; simplification, credited reviewer interests and unclosed contemporaneous/trial finance limit independent efficacy use. No numerical treatment ranking or obsolete approval claim adopted. | Water/food routes, pregnancy and chronic-infection context; geography absolutes excluded |
| NHS hepatitis, December31,2025 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Viral versus other inflammation, treatment categories and HEV precautions |
| CDC viral-hepatitis clinical overview, August29,2025 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Transmission, testing and selected treatment/prevention roles |
| CDC hepatitis C testing, January31,2025 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Reactive antibody versus current RNA-detected infection |
| CDC hepatitis A care, January31,2025 | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; CDC Division of Viral Hepatitis, Atlanta; US clinical/public-health policy. | Tier 1 public education provisionally; original trial and individual contributor chains unclassified. B provisional — dated original body actually read. Public-health accuracy incentive, identifiable policy remit and source links; no complete author/donor/trial clearance. Brand comparisons, efficacy percentages, doses and worldwide schedule rules excluded. | Prompt post-exposure assessment; US timing context, not a personal product plan |
| NHS jaundice, January22,2024 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Urgent assessment of new yellow skin/eyes; adult context |
| NHS vomiting blood, August18,2025 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Bleeding urgency and emergency signs |
| NHS dehydration, May1,2026 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national NHS England education. Use equivalent local urgent/emergency services outside the UK. | Tier 1 public education provisional; author and original treatment-trial finance unclassified. B provisional — actual dated national original checked for the attributed definitions, precautions or warning signs. Public accountability supports accuracy; simplified wording and complete individual/trial financial chain remain unclosed. | Poor-intake warning signs and shock urgency |
| NIDDK actual funding, gifts and location FAQ, May2024 | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional provenance, not actual donor allocation |
| NIDDK budget/legislative index, May2024 review, newer requests listed | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Proposals distinguished from actual appropriations |
| NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table | US NIH/HHS federal research institute: Congressional appropriations and permitted voluntary conditional/unconditional gifts and bequests; actual FAQ. The original budget table reports about $2.33 billion FY2026 enacted institutional funding, kept separate from the FY2027 request. This is not the hepatitis/page budget. Actual gift donors and page allocation unclosed. | United States; NIH/NIDDK, Bethesda, Maryland, with a Phoenix research branch; federal jurisdiction. | Tier 3 institutional financial self-disclosure. B provisional for actual appropriations, gift and location facts. FAQ/index review May2024; actual21-page FY2027 justification printedNIDDK-6/8 separately labels FY2026 enacted, with mandatory type1-diabetes shown separately. The FY2027 request is not enacted finance; actual donors and page allocations unclosed. | Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate |
| NHS national website content and funding policy, October2022 | The national NHS website states DHSC funding and no advertising or corporate sponsorship in its content policy. Policy text is dated October2022; institutional arrangements can change. Complete page-author declarations and underlying treatment-trial finances were not supplied. Hospital trusts have separate income. | United Kingdom; national England patient-information service. | Tier 3 editorial/funding self-disclosure. B provisional — explicit funding and disclosure policy actually read. Dated2022 policy, actual individual declarations and implementation not audited. | National website editorial/financial provenance |
| CDC actual FY2026 operating plan,4pages | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective2016, reviewed2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Whole programme budget, not a page/trial allocation |
| CDC original gift policy, effective2016; reviewed2022,24pages | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective2016, reviewed2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Direct gifts, foundation transfers and conflict-review requirements |
| CDC actual public-site contact/provenance | US CDC/HHS public budget authority and transfers. The FY2026 operating plan lists $46 million for the whole viral-hepatitis programme, not this page or a specific trial. Separate gift policy permits direct gifts, in-kind support and CDC Foundation transfers with conflict review. Actual page donors, reviewers and trial allocations remain unresolved. | United States; Centers for Disease Control and Prevention, Atlanta, Georgia; federal jurisdiction. | Tier 3 financial, policy or contact self-disclosure. B provisional for actual original finance routes. Gift policy effective2016, reviewed2022; permission and conflict rules do not verify actual gifts, implementation or page allocations. | Atlanta institutional location |
| Paul Martin original society financial declaration; period unclosed | Original AASLD profile declares past consultancy for AbbVie, Gilead, Merck and Mallinckrodt. Disclosure period, amounts, complete society backers and any NIDDK-page payment unresolved. | United States; AASLD society profile of University of Miami clinician. Full company ownership/backer chains not cleared. | Tier 3 subject-related author-interest self-disclosure. B provisional for the actual listed declarations; no inference of page sponsorship, improper conduct or a complete current financial audit. | Separate credited-reviewer interests only |
| Lok/Feld original2025 guideline financial declarations,45pages | Actual 2025 AASLD/IDSA guideline accepted-manuscript pages3–4 lists Lok’s monitoring-board/consultancy and Feld’s drug-company consultancy. A draft disclosure placeholder remains elsewhere. Society income, complete original trial funding and the December2024 NIDDK review compensation unclosed. | United States-led guideline with Canadian author affiliations; IDSA-hosted original, DOI10.1097/HEP.0000000000001549. | Tier 3 financially connected authors and direct disclosure. B provisional for selected explicit financial declarations only; full clinical guidance not adopted here. Accepted-manuscript presentation and incomplete funding chain remain visible. | Separate credited-reviewer interests only |
| Sherman original July2026 sponsored-course disclosure | Original July27,2026 PRIME course names Gilead Sciences educational-grant support and lists Kenneth Sherman’s GSK consultancy and Atea research support. Free access and accreditation do not remove sponsorship. PRIME/Everyday Health ownership and full backer chain unclosed. | United States; commercial education producer and US clinician affiliation, with international faculty. Exact headquarters/backer chain not cleared. | Tier 4 company-supported, producer-created educational product. D for financial independence; used only to identify a later separate reviewer relationship. No course clinical or efficacy claim adopted, and no assignment of these payments to the older NIDDK page. | Separate later relationship; course efficacy excluded |
Frequently asked questions
Can I identify the type from jaundice?
No. Symptoms overlap and appropriate testing is needed.
Can hepatitis A become chronic?
No. Prolonged symptoms or relapse is not the same as chronic viral infection.
Does a positive hepatitis C antibody prove current infection?
No. The RNA-testing pathway clarifies current infection, with exceptions needing clinical interpretation.
Can hepatitis D occur without hepatitis B?
The infection requires hepatitis B.
Can hepatitis E occur without foreign travel?
Yes. Relevant food exposure can occur locally.
Does a public-health source certify all treatment trials as independent?
No. Each original trial and financial relationship needs separate review.
Sources and funding notes
- NIDDK viral-hepatitis series, December2024 — Virus-family distinctions and credited outside reviewers.
- NIDDK hepatitis A, December2024 — Acute infection and selected supportive-care precautions.
- NIDDK hepatitis B, December2024 — Persistence, complications and reactivation context.
- NIDDK hepatitis D, December2024 — Dependence on HBV and coinfection/superinfection distinction.
- NIDDK hepatitis E, December2024 — Water/food routes, pregnancy and chronic-infection context; geography absolutes excluded.
- NHS hepatitis, December31,2025 — Viral versus other inflammation, treatment categories and HEV precautions.
- CDC viral-hepatitis clinical overview, August29,2025 — Transmission, testing and selected treatment/prevention roles.
- CDC hepatitis C testing, January31,2025 — Reactive antibody versus current RNA-detected infection.
- CDC hepatitis A care, January31,2025 — Prompt post-exposure assessment; US timing context, not a personal product plan.
- NHS jaundice, January22,2024 — Urgent assessment of new yellow skin/eyes; adult context.
- NHS vomiting blood, August18,2025 — Bleeding urgency and emergency signs.
- NHS dehydration, May1,2026 — Poor-intake warning signs and shock urgency.
- NIDDK actual funding, gifts and location FAQ, May2024 — Institutional provenance, not actual donor allocation.
- NIDDK budget/legislative index, May2024 review, newer requests listed — Proposals distinguished from actual appropriations.
- NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table — Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate.
- NHS national website content and funding policy, October2022 — National website editorial/financial provenance.
- CDC actual FY2026 operating plan,4pages — Whole programme budget, not a page/trial allocation.
- CDC original gift policy, effective2016; reviewed2022,24pages — Direct gifts, foundation transfers and conflict-review requirements.
- CDC actual public-site contact/provenance — Atlanta institutional location.
- Paul Martin original society financial declaration; period unclosed — Separate credited-reviewer interests only.
- Lok/Feld original2025 guideline financial declarations,45pages — Separate credited-reviewer interests only.
- Sherman original July2026 sponsored-course disclosure — Separate later relationship; course efficacy excluded.
Actual December2024 NIDDK overview and selected A/B/D/E bodies, December2025 NHS overview, current CDC overview/testing/care and NHS safety originals checked. Source-specific credited reviewers identified. Later separate author declarations were read in the original society profile, accepted guideline manuscript and commercially funded course; they are not assigned retrospectively to the NIDDK page. Older HEV prevalence/geography absolutes, personal schedules and numerical treatment claims excluded. Current primary patient guidance and the selected financial originals were read. Complete original treatment trials, their suppliers, society ownership/backer chains and contemporaneous page-review compensation were not audited. No personal dose, brand hierarchy or trial benefit percentage is supplied. ClinicalTrials.gov listings, institutional names and accreditation do not themselves establish safety or independence.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.